News & Media

Business - News

MERGER, PARTNERSHIP

Partnership with Oculos Clinical Research

April, 2015 - Ophthalmology-focused CROs, Iris Pharma and Oculos Clinical Research Announce Strategic Alliance to Offer International Specialized Services to the Ophthalmic Market […] Continue reading

 

RxGen

Partnership with RxGen

April, 2012 - Iris Pharma and RxGen (Hamden, CT, USA) Partner to Deliver Seamless and Superior Drug & Medical Devices Development Services in Ophthalmology.[…] Continue reading

 

Institut de la Vision

Joint cooperation with the Institut de la Vision

July, 2008 - The Institut de la Vision (Paris France) and Iris Pharma join forces to strengthen the bond between the private and public sectors, and between industry and academic research […] Continue reading

 

Partnership with Centre de Recherches Biologiques (CERB)

July, 2008 - Iris Pharma has established a partnership with CERB (Baugy, France), a leading international Contract Research Organization (CRO), for non ocular preclinical pharmacology and regulatory toxicology.

 

Clirophtha - Contract Research Organization in Ophthalmology

Merger with Clirophtha

December, 2007 - Iris Pharma, a specialist CRO for pre-clinical research in ophthalmology, has announced the completion of its merger with Clirophtha (La Gaude, France), a unique CRO in Europe and North America that is completely dedicated to ophthalmology clinical trials […] Continue reading

 

Strategic Alliance with Promedica International

April, 2007 - Iris Pharma announced the establishment of a new strategic alliance with Promedica International (PMI), a USA-based Contract Research Organization (CRO), for expansion of ophthalmology clinical research. […] Continue reading

 

LICENCE AGREEMENT

Opia

Licence agreement with Opia Technologies 

April, 2011 - Long-term licence agreement for the development of EYEPRIM®, OPIA Technologies' main device platform in animal studies. As part of the agreement, Iris Pharma has the exclusive licence for the use of EYEPRIM® device to perform ocular surface biopsies of the living eye in its preclinical research activities. Continue reading

 

AWARDS

Pierre-Paul Elena

Prize-winner in the growth category

October, 2010 - The French newspaper "Les Echos" awards Iris Pharma a prize in recognization of its growth performance. Continue reading

Preclinical Models - News

Ocular angiogenesis

DRY EYE MODEL

August, 2013 - Two experimental rodent models using scopolamine, a tropane alkaloid drug with muscarinic antagonist effects, to mimic dry eye syndrome in the human eye […] Continue reading 

 

ENDOTOXIN INDUCED UVEITIS (EIU) MODEL

February, 2011 - Iris Pharma launches new key in vivo model of uveitis […] Continue reading

 

EYE DISCOMFORT MODEL

March, 2010 - A more ethical eye discomfort model to test the efficacy of your compounds in reducing mild ocular pain […] Continue reading

 

DRY AMD MODEL: BLUE LIGHT-INDUCED RETINAL DAMAGE MODEL

March, 2010 - A new model of blue light-induced damage at Iris Pharma targeting the neuroprotection effect […] Continue reading 

 

OCULAR SURGERY - PARTIAL VITRECTOMY

January, 2010 - Our technicians have successfully performed partial vitrectomies in rabbits […] Continue reading

 

EXPERIMENTAL AUTOIMMUNE UVEITIS (EAU) MODEL

December, 2008 - A rat Experimental Autoimmune Uveitis (EAU) model has been developed by the Iris Pharma Research Team. Experimental Autoimmune Uveitis (EAU) is an organ-specific autoimmune disease and serves as a model of certain ocular inflammatory pathologies in human […] Continue reading

 

OCULAR ANGIOGENESIS MODELS

June, 2006 - The Iris Pharma Research Team has validated several animal models to investigate the various aspects of Age-related Macular Degenerescence (AMD) and retinal degenerescence: corneal angiogenesis (suture model on rabbits), retinopathy of prematurity (ROP, hyperoxia model in pup mice), chemical burn (alcohol, sodium hydroxyde models in rats, mice and rabbits), retinal vascular permeability (VEGF-induced leakage) in rabbits and choroidial neovascularization (CNV) model. […] Continue reading

Equipment - News

SPECTRALIS®HRA-OCT AND LUMINEX®LX200 IS

Iris Pharma acquires ultra-top of the range evaluation equipement. The Spectralis® HRA-OCT allows very high precision monitoring of the areas of the retina which have been treated and their evolution. With the Luminex Lx200 analysis system, biochemical quantifications and multiple simultaneous analyses can be carried out in low sample volumes […] Continue reading

 

RRLC-MS/MS

Acquisition of a new RRLC-MS/MS system for clearly superior results in bioanalysis. After a one-year trial period, Iris Pharma had acquired the Agilent 6410 triple quadrupole LCMS. This system dramatically increases the speed of analysis, the volume of sample and the sensitivity and brings the highest level of performance and reliability to Iris Pharma labs.

 

COUNTER BETA TRI-CARB 2900 (Perkin Elmer)

Liquid scintillation analyzer. This instrument measures levels of radioactive elements by counting photonic emissions produced when alpha and beta particles interact with certain reagents (scintillants).

 

CYCLONE PLUS PHOSPHOR IMAGER

Radiometric phosphor imager for quantitative filmless autoradiography.

 

APOTOME

Light microscope using "structured illumination" process for 3D fluorescence imaging.

 

OCT retina

Facilities - News

 

 

NEW PARIS PREMISES AT THE INSTITUT DE LA VISION

December, 2008 - Iris Pharma opens its new Paris (FRANCE) premises at the Institut de la Vision, one of Europe's major research centers dedicated to eye diseases. This collaboration will facilitate the accelerated development of new therapies to benefit patients with impaired vision and suffering from ocular ailments. […] Continue reading

 

GTC

NEW PRECLINICAL TESTING FACILITY

December, 2007 - Due to the steady increase in demand for its services, Iris Pharma has decided to expand its preclinical testing facility […] Continue reading

 

 

Commitment - News

 

OPHTA BIOTECH

ESTABLISHMENT OF OPHTA BIOTECH

February, 2008 - Iris Pharma is one of the co-founders of this new French organization which aims at gathering the French Riviera, Corsica and Monaco-based experts, doctors, industries, researchers, patients organizations and others who have a concern in ophthalmology to better promote the local expertise and know-how in this field around the world. […] Continue reading

 

 

 

Booklets

Iris Pharma Fact Sheet: Click here to download the booklet

 

Preclinical & Clinical Ophthalmology Research services Worldwide: Click here to download the booklet

 

The Côte d'Azur Ophthalmology Cluster: Click here to download the booklet

 

Le Pôle Ophtalmologique de la Côte d'Azur: Click here to download the booklet

 
 
 

 

Newsletters

Newsletter #5 Focus on Iris Pharma clinical services

Newsletter #4 Focus on analytical methods in all ocular matrices and on preclinical formulation service

Newsletter #3 Focus on Iris Pharma preclinical services

Newsletter #2 Focus on Iris Pharma strategic consulting services

Newsletter #1 Focus on Azithromycin eye drop solution

 

Reports

glaucoma research

Guiding clients in new directions for glaucoma.

Click here to download the ARVONews special report.

 

Modeling dry eye syndrome.

Click here to download the ARVONews special report.

 

Special Report: CROs.

Click here to download the ARVONews special report.

 

Contract Research Organizations: From transactional to strategic partnering.

Click here to download the ARVONews special report.